Abstract
AbstractBackgroundAmid COVID‐19 pandemic, issue is raised: 1) whether AD and Very‐late‐onset‐schizophrenia‐like psychosis(VLOSL): “dementia praecox” have higher COVID‐19 risk;2)whether dysregulated cross‐talk of immunity and inflammation, in Inflammasome‐Cytokine‐insulin signaling cascade (IFCI) is the missing link for AD, VLOSL and COVID‐19.MethodOur objective is : 1) to conduct Pub‐med search for crucial role of inflammasome‐cytokine‐insulin cascade(IFCI) in AD, VLOSL and COVID‐10 burden; 2a)to examine using RCT data whether in schizophrenia, cognitive impairment correlates with insulin resistance(IR) and cardio‐metabolic risks (CMR);2b)whether Panax Ginseng, as prime executioner of IFCI, modifies IR,CMR in TRS.ResultIn Part1: our Pubmed search concludes Dementia syndrome carries higher mortality risk. A meta‐analysis of 634,338 COVID‐19 patients from 16 studies reveals that schizophrenia, and dementia, significantly increased risk of COVID‐19 mortality and severity. Cardio‐metabolic risk factors modify the link. A large Swedish cohort study and systematic review of 17studies found evidence of VLOSL carries higher risk of dementia. Aberrant IFCI correlated with COVID‐19 severity, but very few data is available for Long‐COVID‐19 syndrome. Effect sizes cannot be calculated due to sample heterogeneity. In Part 2: post‐hoc analysis of Ginsana‐115 (Boehringer‐Ingelheim‐Pharmaton,Switzerland) of 8‐week placebo‐controlled parallel group design in TRS subjects . Log‐IR(insulin resistance) scores significantly correlated with spatial processing (p = 0.017). Framingham‐Risk‐score correlated inversely with visual perception p = 0.040) and spatial processing (p = 0.029) and neurocognitive index (p = 0.090). Systolic blood pressure (sBP) correlated significantly and inversely with visual perception (p = 0.032),speed (p = 0.010),and spatial processing (p = 0.034), HDL correlated with memory score:p = 0.008. Brief‐Psychiatric‐Rating‐Scale:BPRS correlated significantly with executive reasoning (p = 0.047),memory (p = 0.021), and mental inflexibility (p = 0.026). Ginsana‐115 at 100‐mg/200‐mg significantly reduced FRS by 24.1% compared with 16.1%(P<0.05) and systolic blood pressure (P<0.05) and significantly improved lipid profile in raising HDL and lowering LDL. Ginsana‐115 : 100 mg and 200 mg oral dosage, significantly improved negative symptom of apathy akin to AD.ConclusionInflammasome‐Cytokine‐Insulin signaling (IFCI) appears to be the heuristic model integrating COVID‐19 syndrome, late‐onset schizophrenia overlapping with AD. Longitudinal studies are warranted to validate IFCI as the prime driver. The positive findings of Ginsana‐115 in TRS highlight the therapeutic Pandora box of Diet, drug leads and Exercise targeting specifically the IFCI landscape in COVID‐19 syndrome, AD and VLOSL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.